MedTech Monthly Insights - September 2026

Oct 06, 2026

PE remains selective but active: Sponsors are concentrating capital in scalable, high-quality platforms, while subscale assets continue to face funding pressure.
M&A can still improve despite high rates: Strong strategic balance sheets, valuation resets, and secular growth in AI, smart implants, and procedure volumes can support deal activity even with financing costs remaining elevated.

Capital concentrating at the top: Later-stage, high-quality medtech platforms are attracting outsized checks, while early-stage funding continues to contract.
Late-stage valuation resilience: Despite lower deal volume, de-risked platforms continue to raise large rounds at relatively strong valuations.
Early-stage valuation pressure: Seed and Series A financings are smaller, milestone-driven. Capital scarcity is forcing earlier proof points on clinical data, reimbursement, and commercial pathways.

M&A remains strategically focused: Buyers continue targeting differentiated assets in cardiovascular, neurostimulation, connected care, and workflow technologies, alongside carve-outs and portfolio repositioning.
Care is shifting outside the hospital: More procedures are moving to ASCs and office-based settings, increasing demand for smaller, lower-cost, workflow-efficient technologies.
AI, robotics, and integrated platforms are gaining scale: MedTech companies are combining hardware, imaging, navigation, robotics, software, and data to improve precision, planning, and operating efficiency.
Recurring revenue is becoming more important: SaaS, consumables, and service models are complementing equipment sales, improving revenue visibility, margins, and customer stickiness.
Outsourcing and localization are reshaping operations: OEMs are relying more on specialized CDMOs and EMS providers while diversifying supply chains to reduce capital requirements, tariffs, and geopolitical risk.
China remains a pricing challenge: Volume-based procurement is increasing pricing pressure and forcing global MedTech companies to rethink localization, product positioning, and commercial strategy.